Cathy B Moelans

List of Publications by Year
in descending order

70 papers	1,890 citations	257450 24 h-index	276875 41 g-index
72 all docs	72 docs citations	72 times ranked	3292 citing authors

#	Article	IF	Citations
1	Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. Journal of the National Cancer Institute, 2018, 110, 568-580.	6.3	198
2	Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. Journal of Pathology, 2011, 225, 222-231.	4.5	118
3	Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Research and Treatment, 2010, 120, 1-7.	2.5	104
4	Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Modern Pathology, 2010, 23, 1029-1039.	5.5	90
5	Prognostic value of estrogen receptor Î± and progesterone receptor conversion in distant breast cancer metastases. Cancer, 2012, 118, 4929-4935.	4.1	81
6	Influence of decalcification procedures on immunohistochemistry and molecular pathology in breast cancer. Modern Pathology, 2016, 29, 1460-1470.	5.5	62
7	Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. Cancer Research, 2018, 78, 3112-3121.	0.9	57
8	Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Research and Treatment, 2012, 135, 49-58.	2.5	53
9	Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Research, 2012, 14, R101.	5.0	49
10	Formaldehyde substitute fixatives: effects on nucleic acid preservation. Journal of Clinical Pathology, 2011, 64, 960-967.	2.0	48
11	Formaldehyde Substitute Fixatives. American Journal of Clinical Pathology, 2011, 136, 548-556.	0.7	48
12	Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases. Clinical and Experimental Metastasis, 2019, 36, 29-37.	3.3	47
13	Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cellular Oncology (Dordrecht), 2011, 34, 89-95.	4.4	41
14	Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Modern Pathology, 2010, 23, 62-70.	5.5	38
15	Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Cellular Oncology (Dordrecht), 2011, 34, 475-482.	4.4	38
16	Validation of DNA promoter hypermethylation biomarkers in breast cancer â€" a short report. Cellular Oncology (Dordrecht), 2014, 37, 297-303.	4.4	37
17	Clinical relevance of copy number profiling in oral and oropharyngeal squamous cell carcinoma. Cancer Medicine, 2015, 4, 1525-1535.	2.8	37
18	HER-2/neuTesting and Therapy in Gastroesophageal Adenocarcinoma. Pathology Research International, 2011, 2011, 1-10.	1.4	35

#	Article	IF	Citations
19	Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes. Cancer Letters, 2014, 344, 138-146.	7.2	34
20	HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection. BMC Cancer, 2009, 9, 4.	2.6	32
21	Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases. BMC Cancer, 2014, 14, 864.	2.6	32
22	Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis. ELife, 2018, 7, .	6.0	32
23	Progressive APOBEC3B mRNA expression in distant breast cancer metastases. PLoS ONE, 2017, 12, e0171343.	2.5	31
24	A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity. Journal of the National Cancer Institute, 2017, 109, .	6.3	30
25	HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cellular Oncology, 2009, 31, 1-10.	1.9	28
26	The molecular genetic make-up of male breast cancer. Endocrine-Related Cancer, 2019, 26, 779-794.	3.1	27
27	Promoter hypermethylation using 24-gene array in early head and neck cancer. Epigenetics, 2014, 9, 1220-1227.	2.7	24
28	Unravelling site-specific breast cancer metastasis: a microRNA expression profiling study. Oncotarget, 2017, 8, 3111-3123.	1.8	24
29	DNA promoter hypermethylation in nipple fluid: a potential tool for early breast cancer detection. Oncotarget, 2016, 7, 24778-24791.	1.8	24
30	Optimal Fixation Conditions and DNA Extraction Methods for MLPA Analysis on FFPE Tissue-Derived DNA. American Journal of Clinical Pathology, 2017, 147, aqw205.	0.7	22
31	Methylation-Specific Multiplex Ligation-Dependent Probe Amplification (MS-MLPA). Methods in Molecular Biology, 2018, 1708, 537-549.	0.9	22
32	Molecular Differences between Ductal CarcinomaIn Situand Adjacent Invasive Breast Carcinoma: A Multiplex Ligation-Dependent Probe Amplification Study. Analytical Cellular Pathology, 2010, 33, 165-173.	1.4	21
33	Clonal intratumor heterogeneity of promoter hypermethylation in breast cancer by MS-MLPA. Modern Pathology, 2014, 27, 869-874.	5.5	20
34	Analysis of copy number changes on chromosome 16q in male breast cancer by multiplex ligation-dependent probe amplification. Modern Pathology, 2013, 26, 1461-1467.	5.5	19
35	<scp>FOXA</scp>1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome. Molecular Oncology, 2018, 12, 1884-1894.	4.6	19
36	ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Cellular Oncology (Dordrecht), 2011, 34, 489-494.	4.4	18

#	Article	IF	Citations
37	ESR1 Amplification is Rare in Breast Cancer and is Associated with High Grade and High Proliferation: A Multiplex Ligation-Dependent Probe Amplification Study. Analytical Cellular Pathology, 2010, 33, 13-18.	1.4	16
38	Implications of rarity of chromosome 17 polysomy in breast cancer. Lancet Oncology, The, 2011, 12, 1087-1089.	10.7	16
39	Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Analytical Cellular Pathology, 2010, 33, 165-73.	1.4	16
40	ESR1 Amplification in Breast Cancer by Optimized RNase FISH: Frequent but Low-Level and Heterogeneous. PLoS ONE, 2013, 8, e84189.	2.5	14
41	Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy. Oncotarget, 2017, 8, 55550-55561.	1.8	14
42	Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer. Oncotarget, 2018, 9, 17078-17092.	1.8	14
43	Chromosome 17 copy number changes in male breast cancer. Cellular Oncology (Dordrecht), 2015, 38, 237-245.	4.4	12
44	Promoter hypermethylation profiling of distant breast cancer metastases. Breast Cancer Research and Treatment, 2015, 151, 41-55.	2.5	11
45	Methylation biomarkers for pleomorphic lobular breast cancer - a short report. Cellular Oncology (Dordrecht), 2015, 38, 397-405.	4.4	10
46	PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer. Targeted Oncology, 2018, 13, 769-777.	3.6	10
47	Role of columnar cell lesions in breast carcinogenesis: analysis of chromosome 16 copy number changes by multiplex ligation-dependent probe amplification. Modern Pathology, 2018, 31, 1816-1833.	5.5	10
48	Lessons Learned from Setting Up a Prospective, Longitudinal, Multicenter Study with Women at High Risk for Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 441-449.	2.5	10
49	ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study. Analytical Cellular Pathology, 2010, 33, 13-8.	1.4	10
50	Molecular profile of nasopharyngeal carcinoma: analysing tumour suppressor gene promoter hypermethylation by multiplex ligation-dependent probe amplification. Journal of Clinical Pathology, 2018, 71, 351-359.	2.0	8
51	Methylation Profile of X-Chromosomeâ€“Related Genes in Male Breast Cancer. Frontiers in Oncology, 2020, 10, 784.	2.8	8
52	Promoter hypermethylation in ductal carcinoma in situ of the male breast. Endocrine-Related Cancer, 2019, 26, 575-584.	3.1	8
53	CEP17 copy number increase does not indicate polysomy 17. Journal of Clinical Pathology, 2014, 67, 454.1-455.	2.0	7
54	Validation of a fully automated HER2 staining kit in breast cancer. Cellular Oncology, 2010, 32, 149-55.	1.9	7

#	Article	IF	Citations
55	Nipple Aspirate Fluid at a Glance. Cancers, 2022, 14, 159.	3.7	7
56	Copy number profiling of oncogenes in ductal carcinoma in situ of the male breast. Endocrine-Related Cancer, 2018, 25, 173-184.	3.1	6
57	Application of Nipple Aspirate Fluid miRNA Profiles for Early Breast Cancer Detection and Management. International Journal of Molecular Sciences, 2019, 20, 5814.	4.1	6
58	OUP accepted manuscript. Clinical Chemistry, 2022, , .	3.2	5
59	The Physiological MicroRNA Landscape in Nipple Aspirate Fluid: Differences and Similarities with Breast Tissue, Breast Milk, Plasma and Serum. International Journal of Molecular Sciences, 2020, 21, 8466.	4.1	4
60	The changing microRNA landscape by color and cloudiness: a cautionary tale for nipple aspirate fluid biomarker analysis. Cellular Oncology (Dordrecht), 2021, 44, 1339-1349.	4.4	4
61	Differences in cancer gene copy number alterations between Epsteinâ€Barr virusâ€positive and Epsteinâ€Barr virusâ€negative nasopharyngeal carcinoma. Head and Neck, 2018, 40, 1986-1998.	2.0	3
62	Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification of Microdissected Tissue. Methods in Molecular Biology, 2011, 755, 107-118.	0.9	3
63	Genomic copy number alterations as biomarkers for triple negative pregnancy-associated breast cancer. Cellular Oncology (Dordrecht), 2022, 45, 591-600.	4.4	3
64	Added Value of HER-2 Amplification Testing by Multiplex Ligation-Dependent Probe Amplification in Invasive Breast Cancer. PLoS ONE, 2013, 8, e82018.	2.5	2
65	Heterogeneity in Signaling Pathway Activity within Primary and between Primary and Metastatic Breast Cancer. Cancers, 2021, 13, 1345.	3.7	2
66	HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization. Analytical Cellular Pathology, 2009, 31, 1-10.	1.4	2
67	Validation of a Fully Automated HER2 Staining Kit in Breast Cancer. Analytical Cellular Pathology, 2010, 32, 149-155.	1.4	1
68	Multiplex Ligation-Dependent Probe Amplification to Detect HER2 Amplification in Breast Cancer: New Insights in Optimal Cut-Off Value. Analytical Cellular Pathology, 2010, 32, 311-312.	1.4	1
69	Response to A. Matikas et al.. Journal of the National Cancer Institute, 2018, 110, 1282-1283.	6.3	0
70	Patient-centered research: how do women tolerate nipple fluid aspiration as a potential screening tool for breast cancer?. BMC Cancer, 2022, 22, .	2.6	0